New drug LY3985297 passes first safety check in healthy volunteers
NCT ID NCT06395012
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug, LY3985297, in 140 healthy volunteers to see if it is safe and how the body processes it. Participants received either a single dose or multiple doses of the drug or a placebo, given through a vein or under the skin. The study is complete and focused on safety and drug levels in the blood, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY3985297
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenExel ACT
Anaheim, California, 92801, United States
-
ICON
Salt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test